BRAINSTORM CELL THERAPEUTICS INC. Increase (Decrease) in Accrued Liabilities
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Increase (Decrease) in Accrued Liabilities of $564.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $564.00K.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $194.00K, a 52.91% decline year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for the quarter ending 2025-06-30 was -$412.00K.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for the quarter ending 2025-03-31 was $412.00K.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for fiscal 2025 was $716.00K, a 575.47% increase from fiscal 2024.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for fiscal 2024 was $106.00K, a 90.31% decline from fiscal 2023.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for fiscal 2023 was $1.09M.
- BRAINSTORM CELL THERAPEUTICS INC. increase (decrease) in accrued liabilities for fiscal 2022 was -$7.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|
| 2026-06-30 | $564.00K 10-Q · filed 2026-08-14 | $758.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $194.00K 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $716.00K 10-K · filed 2026-03-31 | ||
| 2025-06-30 | -$412.00K 10-Q · filed 2026-08-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | |
| 2025-03-31 | $412.00K 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | $106.00K 10-K · filed 2026-03-31 | ||
| 2023-12-31 | $1.09M 10-K · filed 2025-03-31 | ||
| 2022-12-31 | -$7.00K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |